Plantar fasciitis

disease
On this page

Summary

Plantar fasciitis (MONDO:0004833) is a disease and 112 clinical trials. Top therapeutic interventions include cortisone acetate, abobotulinumtoxina, and botulinum toxin type a. A subtype of fasciitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 112

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameplantar fasciitis
Mondo IDMONDO:0004833
MeSHD036981
DOIDDOID:9600
ICD-11254630809
SNOMED CT202882003
UMLSC0149756
MedGen56201
Is cancer (heuristic)no

Disease family

This is a subtype of fasciitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorderfasciitisplantar fasciitis

Related subtypes (5): nodular fasciitis, proliferative fasciitis, ischemic fasciitis, necrotizing fasciitis, eosinophilic fasciitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
Sodium ChloridePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Abobotulinumtoxina, Bupivacaine, Daxibotulinumtoxina, Dexamethasone, Methylprednisolone, Onabotulinumtoxina.

Clinical trials & evidence

Clinical trials

Clinical trials: 112.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified87
PHASE410
PHASE26
PHASE2/PHASE34
PHASE33
PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00189592PHASE4COMPLETEDPlantar Fasciosis Treatment Using Coblation
NCT00222911PHASE4COMPLETEDTreatment of Plantar Fasciitis With Dorsiflexion Night Splints and Medial Arch Supports
NCT00758641PHASE4COMPLETEDPlatelet Rich Plasma to Treat Plantar Fasciitis
NCT00888394PHASE4COMPLETEDEffectiveness of Podiatry on Plantar Pain
NCT01326351PHASE4UNKNOWNProlotherapy for the Treatment of Plantar Fasciitis
NCT01509274PHASE4UNKNOWNTreatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia
NCT01588730PHASE4TERMINATEDDynamic and Static Splinting as a Treatment for Plantar Faciiopathy
NCT01994759PHASE4COMPLETEDOptimal Treatment of Plantar Fasciitis: Physical Training, Glucocorticoid Injections or a Combination Thereof.
NCT02448316PHASE4COMPLETEDPlantar Fasciitis, Operation or Conservative Treatment
NCT02608723PHASE4COMPLETEDShock Wave Therapy: Do the External Appearance of the Device Influence Clinical Outcomes?
NCT00447876PHASE2/PHASE3COMPLETEDStudy to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
NCT00720694PHASE3COMPLETEDStudy of Effectiveness and Safety of Extracorporeal Shock Wave Therapy (ESWT) for Treatment of Painful Heel Syndrome
NCT01017406PHASE3UNKNOWNHeel Cushion for Plantar Fasciitis
NCT01431066PHASE3COMPLETEDActiPatch Plantar Fasciitis Clinical Trial
NCT01786057PHASE2/PHASE3UNKNOWNEffect of Extracorporeal Shock Wave Therapy of Gastrosoleus Trigger Points in Patients With Plantar Fasciitis
NCT01957631PHASE2/PHASE3WITHDRAWNComparing Steroid Injections and Platelet Rich Plasma Injections in the Treatment of Plantar Fasciitis
NCT05367271PHASE2/PHASE3COMPLETEDThe Efficacy of Botulinum Toxin vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis
NCT07587255PHASE2NOT_YET_RECRUITINGEfficacy of Extracorporeal Shockwave Therapy on Plantar Fasciitis in Patients With Peripheral Neuropathy
NCT02973269PHASE2TERMINATEDDaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
NCT03137407PHASE2COMPLETEDPhase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
NCT03825315PHASE2COMPLETEDDaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
NCT03978234PHASE2UNKNOWNEvaluating the Safety and Effect of abobotulinumtoxinA in the Gastrocnemius Muscle to Improve Equinus and Plantar Fasciitis Pain
NCT06169319PHASE2COMPLETEDA Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)
NCT07395128PHASE1RECRUITINGLateral Plantar Artery Embolization For Plantar Fasciitis
NCT05868577PHASE1COMPLETEDInfracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis
NCT02196155Not specifiedRECRUITINGBotulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis
NCT05075005Not specifiedRECRUITINGThe Effects of Terrain Variation on Intrinsic Foot Musculature in Healthy Individuals and Individuals With Plantar Fasciitis
NCT05216679Not specifiedRECRUITINGNovel Stretching Device Versus Night Splints
NCT06542211Not specifiedRECRUITINGObservation on the Efficacy of Improving Ankle Dorsiflexion Limitation in Patients With Plantar Fasciitis
NCT06563492Not specifiedNOT_YET_RECRUITINGThe Effect of Insoles in Plantar Fasciitis
NCT06589037Not specifiedNOT_YET_RECRUITING“Comparison of Shockwave Application on the Sole of the Foot Vs. the Back of the Leg in the Treatment of Plantar Fasciitis: a Clinical Trial.”
NCT06674902Not specifiedNOT_YET_RECRUITINGElectrolysis in Patients With Chronic Plantar Fasciitis
NCT06967168Not specifiedRECRUITINGHeEL Pain Pathways Feasibility Study
NCT07006389Not specifiedENROLLING_BY_INVITATIONFactors Affecting Response to Extracorporeal Shock Wave Therapy in Plantar Fasciitis: A Cross-sectional Clinical Study
NCT07057505Not specifiedNOT_YET_RECRUITINGPain and Fascia Thickness After Steroid Injection in Plantar Fasciitis
NCT07060352Not specifiedNOT_YET_RECRUITINGEstimating the Prevalence of GAstrocnemius Muscle REtraction in a Population Suffering From Plantar aPOneurositis and Describing the Effects of Lengthening
NCT07070245Not specifiedENROLLING_BY_INVITATIONComparing Instrument Assisted Soft Tissue Mobilization With Positional Release Technique for Plantar Fasciitis Pain and Range of Motion
NCT07151066Not specifiedENROLLING_BY_INVITATIONAnthropometric Parameters of the Foot and Plantar Fasciitis
NCT07179666Not specifiedNOT_YET_RECRUITINGComparing Neural Mobilization and Traditional Physiotherapy in Plantar Fasciitis Patients
NCT07182201Not specifiedNOT_YET_RECRUITINGEffect of Foot Core Control Training on Dorsiflexion Function and Gait Biomechanical Characteristics of Patients With Chronic Plantar Fasciitis

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CORTISONE ACETATE42
ABOBOTULINUMTOXINA41
BOTULINUM TOXIN TYPE A41
ETHIODIZED OIL41
LIDOCAINE41
SODIUM CHLORIDE41
CORTISONE32
CHEMBL149731302